Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK

RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer

(2015) Hiroki Imaoka et al.   CARCINOGENESIS

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutant NRASQ61 shares signaling similarities across various cancer types – potential implications for future therapies

(2015) Igor Vujic et al.   Oncotarget

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma

(2014) M. A. Smit et al.   Molecular Systems Biology

Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma

(2014) Vito W. Rebecca et al.   Pigment Cell & Melanoma Research

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis

(2013) Lin Zhou et al.   FASEB JOURNAL

Cutaneous melanoma

(2013) Alexander MM Eggermont et al.   LANCET

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

(2013) C. Posch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer

(2012) R. A. Patel et al.   CANCER RESEARCH

Changes in Ect2 Localization Couple Actomyosin-Dependent Cell Shape Changes to Mitotic Progression

(2012) Helen K. Matthews et al.   DEVELOPMENTAL CELL

Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy

(2012) Nicola Rath et al.   EMBO REPORTS

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis

(2012) L. C. W. Vredeveld et al.   GENES & DEVELOPMENT

Analysis of 20 genes at chromosome band 12q13:RACGAP1andMCRS1overexpression in nonsmall-cell lung cancer

(2012) Yurong Liang et al.   GENES CHROMOSOMES & CANCER

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Next-generation proteomics: towards an integrative view of proteome dynamics

(2012) A. F. Maarten Altelaar et al.   NATURE REVIEWS GENETICS

The Proteomics Identifications (PRIDE) database and associated tools: status in 2013

(2012) Juan Antonio Vizcaíno et al.   NUCLEIC ACIDS RESEARCH

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

(2012) I V Fedorenko et al.   ONCOGENE

Delving into somatic variation in sporadic melanoma

(2012) Vijay Walia et al.   Pigment Cell & Melanoma Research

Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening

(2012) Matthew A. Held et al.   Cancer Discovery

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties

(2011) Mahmoud Alhosin et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways

(2011) Yongmei Feng et al.   Pigment Cell & Melanoma Research

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Targeting the RAS pathway in melanoma

(2011) Zhenyu Ji et al.   TRENDS IN MOLECULAR MEDICINE

In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes

(2010) Kwang-Hoon Chun et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

(2010) J. R. Dry et al.   CANCER RESEARCH

Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity

(2010) Mutsuki Amano et al.   Cytoskeleton

Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells

(2009) T. Ueki et al.   CANCER RESEARCH

Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control

(2009) Alex M. Aronov et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of direct transcriptional targets ofV600EBRAF/MEK signalling in melanoma

(2009) Leisl M Packer et al.   Pigment Cell & Melanoma Research

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY